KR960041159A - 도파민(dopamine)의 재흡수를 억제하기 위한(알파- 아미노메틸-3,4-디클로로벤질)-티오아세트아미드 유도체들의 이용과 이러한 용도로 사용되는 새로운 화합물들 - Google Patents

도파민(dopamine)의 재흡수를 억제하기 위한(알파- 아미노메틸-3,4-디클로로벤질)-티오아세트아미드 유도체들의 이용과 이러한 용도로 사용되는 새로운 화합물들 Download PDF

Info

Publication number
KR960041159A
KR960041159A KR1019960016765A KR19960016765A KR960041159A KR 960041159 A KR960041159 A KR 960041159A KR 1019960016765 A KR1019960016765 A KR 1019960016765A KR 19960016765 A KR19960016765 A KR 19960016765A KR 960041159 A KR960041159 A KR 960041159A
Authority
KR
South Korea
Prior art keywords
dichlorobenzyl
thioacetamide
tert
isomers
alpha
Prior art date
Application number
KR1019960016765A
Other languages
English (en)
Inventor
로랑 필리페
Original Assignee
파. 세. 라퐁
라보라뜨와르 엘르 라퐁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파. 세. 라퐁, 라보라뜨와르 엘르 라퐁 filed Critical 파. 세. 라퐁
Publication of KR960041159A publication Critical patent/KR960041159A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 도파민(dopamine) 재흡수를 억제하기 위한,〔α-(터트-부틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 좌회전성 이성질체,〔α-(터트-아밀아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 이성질체들,〔α-(1-아다만틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 이성질체들로부터 선택된 화합물과, 약학적으로 허용가능한 산을 함유하는 이 화합물들의 부가염들의 이용에 관한 것이다.

Description

도파민(dopamine)의 재흡수를 억제하기 위한 (α-아미노메틸-3,4-디클로로벤질)-티오아세트아미드 유도체들의 이용과 이러한 용도로 사용되는 새로운 화합물들
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 도파민(dopamine) 재흡수를 억제하므로써 환자를 치료하는데 사용하는,〔α-(터트-부틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 좌회전성 이성질체,〔α-(터트-아밀아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 이성질체들,〔α-(1-아다만틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 이성질체들 및, 약제학적으로 허용가능한 산을 함유하는 상기 화합물들의 부가 염들로부터 선택되는 화합물.
  2. 쾌감결여증(anhedonia)의 치료에 사용하는,〔α-(터트-부틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 좌회전성 이성질체,〔α-(터트-아밀아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 이성질체들,〔α-(1-아다만틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 이성질체들 및, 약제학적으로 허용가능한 산을 함유하는 상기 화합물들의 부가염들로부터 선택되는 화합물.
  3. 인식의 자극(stimulating cognition)의 치료에 사용하는,〔α-(터트-부틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 좌회전성 이성질체,〔α-(터트-아밀아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 이성질체들,〔α-(1-아다만틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 이성질체들 및, 약제학적으로 허용가능한 산을 함유하는 상기 화합물들의 부가염들로부터 선택되는 화합물.
  4. 긴장형(catatonic-type) 정신분열증의 치료에 사용되는,〔α-(터트-부틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 좌회전성 이성질체,〔α-(터트-아밀아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 이성질체들,〔α-(1-아다만틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 이성질체들 및, 약제학적으로 허용가능한 산을 함유하는 상기 화합물들의 부가염들로부터 선택되는 화합물.
  5. 파킨슨씨 병의 치료에 사용되는,〔α-(터트-부틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 좌회전성 이성질체,〔α-(터트-아밀아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 이성질체들,〔α-(1-아다만틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 이성질체들 및, 약제학적으로 허용가능한 산을 함유하는 상기 화합물들의 부가염들로부터 선택되는 화합물.
  6. 약물중독의 치료에 사용되는,〔α-(터트-부틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 좌회전성 이성질체,〔α-(터트-아밀아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 이성질체들,〔α-(1-아다만틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 이성질체들 및, 약제학적으로 허용가능한 산을 함유하는 상기 화합물들의 부가염들로부터 선택되는 화합물.
  7. 제1항에 있어서, 상기 화합물은〔α-(터트-부틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 좌회전성 이성질체로부터 선택되는 것을 특징으로 하는 화합물.
  8. 제7항에 있어서, 상기 화합물은 좌회전성 이성질체임을 특징으로 하는 화합물.
  9. 〔α-(터트-부틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 좌회전성 이성질체와, 약제학적으로 허용가능한 산을 함유하는 그것의 부가염들.
  10. 〔α-(터트-부틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드와 그 좌회전성 이성질체의 염산염.
  11. 〔α-(터트-아밀아미노메틸)-3,4-디클로로벤질〕티오아세트아미드 및 그 이성질체들과, 약제학적으로 허용가능한 산을 함유하는 이 화합물들의 부가염들.
  12. 〔α-(1-아다만틸아미노메틸)-3,4-디클로로벤질〕티오아세트아미드 및 그 이성질체들과, 약제학적으로 허용가능한 산을 함유하는 이 화합물들의 부가염들.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960016765A 1995-05-19 1996-05-17 도파민(dopamine)의 재흡수를 억제하기 위한(알파- 아미노메틸-3,4-디클로로벤질)-티오아세트아미드 유도체들의 이용과 이러한 용도로 사용되는 새로운 화합물들 KR960041159A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9506000A FR2734264B1 (fr) 1995-05-19 1995-05-19 Utilisation de derives d'alpha-aminomethyl-3,4-dichlorobenzyl-thioacetamide pour la fabrication d'un medicament inhibant la recapture de la dopamine et nouveaux composes pour cette utilisation
FR9506000 1995-05-19

Publications (1)

Publication Number Publication Date
KR960041159A true KR960041159A (ko) 1996-12-19

Family

ID=9479198

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960016765A KR960041159A (ko) 1995-05-19 1996-05-17 도파민(dopamine)의 재흡수를 억제하기 위한(알파- 아미노메틸-3,4-디클로로벤질)-티오아세트아미드 유도체들의 이용과 이러한 용도로 사용되는 새로운 화합물들

Country Status (14)

Country Link
US (2) US5795915A (ko)
EP (1) EP0743063B1 (ko)
JP (1) JP3926867B2 (ko)
KR (1) KR960041159A (ko)
AT (1) ATE213157T1 (ko)
AU (1) AU713215B2 (ko)
CA (1) CA2176654A1 (ko)
DE (1) DE69619156T2 (ko)
DK (1) DK0743063T3 (ko)
ES (1) ES2172644T3 (ko)
FR (1) FR2734264B1 (ko)
NZ (1) NZ286602A (ko)
PT (1) PT743063E (ko)
ZA (1) ZA963846B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11162829A (ja) * 1997-11-21 1999-06-18 Nec Corp 半導体装置の製造方法
JP3649279B2 (ja) * 1998-12-25 2005-05-18 日立化成工業株式会社 基板の研磨方法
US7160899B2 (en) 2001-04-09 2007-01-09 Neurosearch A/S Adenosine A2A receptor antangonists combined with neurotrophic activity compounds in the treatment of Parkinson's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2561646B1 (fr) * 1984-03-23 1987-10-09 Lafon Labor Derives d'acide (a-(alkylaminomethyl)-benzyl)-thioacetique, procede de preparation et utilisation en therapeutique
FR2648814B1 (fr) * 1989-06-26 1991-10-18 Lafon Labor L'alpha (tert-butyl-aminomethyl-3,4-dichlorobenzyl)thioacetamide, son procede de preparation et son application en therapeutique
WO2001058545A1 (en) 2000-02-08 2001-08-16 Francois Vermeulen Smit Method of and apparatus for operating a video lottery terminal

Also Published As

Publication number Publication date
AU713215B2 (en) 1999-11-25
EP0743063B1 (fr) 2002-02-13
JP3926867B2 (ja) 2007-06-06
CA2176654A1 (en) 1996-11-20
JPH093039A (ja) 1997-01-07
AU5233896A (en) 1996-11-28
DK0743063T3 (da) 2002-06-03
PT743063E (pt) 2002-07-31
ATE213157T1 (de) 2002-02-15
US6268397B1 (en) 2001-07-31
US5795915A (en) 1998-08-18
FR2734264A1 (fr) 1996-11-22
EP0743063A1 (fr) 1996-11-20
ZA963846B (en) 1997-11-17
ES2172644T3 (es) 2002-10-01
NZ286602A (en) 1997-04-24
FR2734264B1 (fr) 1997-08-01
DE69619156D1 (de) 2002-03-21
DE69619156T2 (de) 2002-08-14

Similar Documents

Publication Publication Date Title
JP3553083B2 (ja) 末梢性活性抗痛覚過敏オピエート
TW592698B (en) Remedy with antidepressant effects
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
IN2015DN01132A (ko)
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
KR950703953A (ko) 2-아미노-6-n-프로필아미노-4, 5, 6, 7-테트라하이드로벤조티아졸(프라미펙솔)의 항우울제로서의 용도(Use of 2-amino-6-n-propylamino-4, 5, 6, 7-tetrahydrobenzothiazole (pramipexol)as an antidepressant drug)
US20050119249A1 (en) Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
KR970025615A (ko) 암 전이 억제제
AR043259A1 (es) Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello
DE69333387D1 (de) Pharmazeutische Zusammensetzungen enthaltend Norastemizol.
GEP20012389B (en) Benzoxazinone Dopamine D4 Receptor Antagonists, Pharmaceutical Composition Containing the Same and Method for Treatment of Psychosis or Schizophrenia
WO2002034267A8 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
KR960041159A (ko) 도파민(dopamine)의 재흡수를 억제하기 위한(알파- 아미노메틸-3,4-디클로로벤질)-티오아세트아미드 유도체들의 이용과 이러한 용도로 사용되는 새로운 화합물들
KR950701922A (ko) 치환된 트리아졸의 설페이트 염, 이를 포함하는 약제학적 조성물 및 치료요법에서의 이의 용도(The sulphate salt of a substituted triazole, pharmaceutical compositions thereof and their use in therapy)
KR910018348A (ko) 술포닐아미노치환 비시클로환계 히드록삼산 유도체
EP1576985A1 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
BR0316131A (pt) Acetil-l-carnitina para a prevenção e/ou tratamento de neuropatias periféricas induzidas por agentes anti-câncer
IL43820A (en) Pharmacological preparations for the treatment of deformed disabled, containing symptomatic aminophytic bronchodilators
SE9900190D0 (sv) New compounds
KR910018028A (ko) 15- 데히드록시-16-옥소프로스타글란딘 화합물에 의한 생화학적 치료
KR910004190A (ko) 온단세트론의 신규 의학 용도
KR880013556A (ko) 도파민수용체 효능제의 용도
NO20013480L (no) Legemiddel for torr hud

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application